At the AUA Meeting – Does Provenge Provide Better Survival Numbers?
The recent AUA meetings in Atlanta had a number of interesting abstracts presented that concern men with advanced prostate cancer. Some of the more interesting abstracts were look back analysis of sipuleucel-T (Provenge) done by [...]
On the Horizon – TOK-001 (Galeterone)
Tokai, a Cambridge, MA based Pharmaceutical company, just presented a promising set of Phase I data pointing to the early efficacy of its "triple whammy" pill for castration-resistant prostate cancer, TOK-001 or galeterone. In their [...]
Zytiga – When Should We Discontinue Using It?
I have had a number of recent conversations with men with advanced prostate cancer who have been taking Abiraterone Acetate (Zytiga). The question that comes up in regular conversation is about knowing when Zytiga has [...]
A New Genetic Technique Predicts Prostate Cancer Relapse
According to a study published online May 9 in The American Journal of Pathology copy number variations (CNV) in both malignant and benign prostate tissue is predictive of prostate cancer relapse. The research performed at [...]
The U.S. Preventive Services Task Force (USPSTF) Down Grades PSA Testing
Today, the U.S. Preventive Services Task Force (USPSTF) posted its prostate cancer screening final recommendation statement. The following letter was received by anyone who posted a public comment: The USPSTF is committed to making the [...]
More Information on the Expanded Access Trial for Alpharadin (Radium-223)
Radium-223 Chloride (Alpharadin) is now available for the treatment of men with advanced prostate cancer who have symptomatic bone metastases (painful) and who are also castration-resistant (hormone-refractory). This is an expanded access program that will [...]